Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

9 Meters Biopharma Inc (NMTR) USD0.001

Sell:$1.30 Buy:$1.34 Change: $0.06 (4.84%)
Market closed |  Prices as at close on 22 September 2021 | Switch to live prices |
Change: $0.06 (4.84%)
Market closed |  Prices as at close on 22 September 2021 | Switch to live prices |
Change: $0.06 (4.84%)
Market closed |  Prices as at close on 22 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. Its pipeline includes NM-002, Larazotide, NM-003, NM-004, NM-102 and NM-004. NM-002 is a long-acting injectable GLP-1 analogue for short bowel syndrome (SBS). Larazotide is an orally administered, gut-restricted tight-junction regulator for celiac disease. NM-003 is a GLP-2 analogue, under orphan indication selection. NM -004 is an immunomodulator, granted pediatric orphan designation in ulcerative colitis. NM-102, a small molecule peptide, is being developed as a potential microbiome modulator and undergoing an indication selection process. NM-004 is patent-protected and has orphan designation for pediatric ulcerative colitis.

Contact details

8480 Honeycutt Rd Ste 120
United States
+1 (919) 2751933

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$315.89 million
Shares in issue:
254.75 million
United States
US dollar

Key personnel

  • John Temperato
    President, Chief Executive Officer, Director
  • Edward Sitar
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.